Risk of new-onset diabetes after long-term treatment with clozapine in comparison to other antipsychotics in patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 36, Issue 2, 2016, Pages 115-119

  Schulte, Peter F J ^a   Bocxe, Johanna T H ^b   Doodeman, Hieronymus J ^c   Van Haelst, Ingrid M M ^c   Cohen, Dan ^d  

^a Mental Health Service North Holland North   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Location Alkmaar   (Netherlands)

^d Mental Health Services North Holland North   (Netherlands)

Author keywords

clozapine; diabetes; long term treatment; retrospective cohort study

Indexed keywords

CLOZAPINE; GLUCOSE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTRIBUTABLE RISK; BLOOD CELL COUNT; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; BLOOD; CHEMICALLY INDUCED; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84957916512     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000465     Document Type: Article

References (32)

1. Dutch Clozapine Collaboration Group. Guideline for the use of clozapine [English version]. 2013. [Cited 22nd October 2015]. Available at: http://www.clozapinepluswerkgroep.nl/wp-content/uploads/2013/07/Guideline-for-the-use-of-Clozapine-2013.pdf. Accessed October 22, 2015.
2. Schulte P,. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother. 2006; 40: 683-688.
3. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27: 596-601.
4. Newcomer JW,. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005; 19: 1-93.
5. Henderson DC, Cagliero E, Gray C, Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000; 157: 975-981.
6. Gianfrancesco FD, Grogg AL, Mahmoud RA, Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002; 63: 920-930.
7. Cohen D, Dekker JJ, Peen J, Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. Eur Neuropsychopharmacol. 2006; 16: 187-194.
8. Cohen D, Stolk RP, Grobbee DE, Hyperglycaemia and diabetes mellitus in patients with schizophrenia or schizo-affective disorders. Diabetes Care. 2006; 29: 786-791.
9. Henderson DC, Nguyen DD, Copeland PM, Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005; 66: 1116-1121.
10. Kelly AC, Sheitman BB, Hamer RM, A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses. J Clin Psychopharmacol. 2014; 34: 441-445.
11. Feng S, Melkersson K,. Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine. Neuro Endocrinol Lett. 2012; 33: 493-498.
12. De Hert MA, Van Winkel R, Van Eyck D, Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006; 83: 87-93.
13. Tenback DE, Van Kessel F, Jessurun J, Risk factors for inactivity in patients in long-term care with severe mental illness [in Dutch]. Tijdschr Psychiatr. 2013; 55: 83-91.
14. Hägg S, Joelsson L, Mjörndal T, Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998; 59: 294-299.
15. Girgis RR, Phillips MR, Li X, Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry. 2011; 199: 281-288.
16. Wu RR, Zhao JP, Liu ZN, Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl). 2006; 186: 572-578.
17. McEvoy JP, Lieberman JA, Stroup TS, Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006; 163: 600-610.
18. Lindenmayer JP, Czobor P, Volavka J, Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003; 160: 290-296.
19. Wang PS, Glynn RJ, Ganz DA, Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol. 2002; 22: 236-243.
20. Liao CH, Chang CS, Wei WC, Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res. 2011; 126: 110-116.
21. Philippe A, Vaiva G, Casadebaig F,. Data on diabetes from the French cohort study in schizophrenia. Eur Psychiatry. 2005; 20 (suppl 4): S340-S344.
22. Hsu JH, Chien IC, Lin CH, Incidence of diabetes in patients with schizophrenia: a population-based study. Can J Psychiatry. 2011; 56: 19-26.
23. Yood MU, DeLorenze G, Quesenberry CP Jr, The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf. 2009; 18: 791-799.
24. Nielsen J, Skadhede S, Correll CU,. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology. 2010; 35: 1997-2004.
25. Kessing LV, Thomsen AF, Mogensen UB, Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010; 197: 266-271.
26. Taylor DM, Douglas-Hall P, Olofinjana B, Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. Br J Psychiatry. 2009; 194: 165-167.
27. Davis MC, Fuller MA, Strauss ME, Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. Acta Psychiatr Scand. 2014; 130: 30-39.
28. Tiihonen J, Lönnqvist J, Wahlbeck K, 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009; 374: 620-627.
29. De Hert M, Correll CU, Cohen D,. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res. 2010; 117: 68-74.
30. Gjerden P, Slordal L, Bramness JG,. Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up. Eur J Clin Pharmacol. 2010; 66: 911-917.
31. Sharpe JK, Stedman TJ, Byrne NM, Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry. 2006; 40: 810-814.
32. Baptista T, Martínez J, Lacruz A, Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry. 2006; 51: 192-196.